Cantor Fitzgerald Boosts Eli Lilly and Company (NYSE:LLY) Price Target to $1,410.00

Key Points

• Cantor Fitzgerald raised Eli Lilly’s price target to $1,410 from $1,350 and maintained an “overweight” rating, implying roughly 20.5% upside. The broader analyst consensus is “Moderate Buy,” with a $1,289.36 average price target.
• Lilly reported a strong quarter, with revenue of $22.97 billion—up 47.7% year over year—and EPS of $8.38, beating estimates of $20.69 billion and $6.16, respectively. The company also issued fiscal 2026 EPS guidance of $35.50 to $36.50.
• Demand for GLP-1 drugs Mounjaro and Zepbound remains the primary growth driver, though Lilly’s premium valuation, reliance on these products and potential manufacturing constraints remain key risks.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its target price raised by equities researchers at Cantor Fitzgerald from $1,350.00 to $1,410.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Cantor Fitzgerald's price target would suggest a potential upside of 20.48% from the stock's current price.

A number of other analysts have also recently weighed in on LLY. Wolfe Research reiterated an "outperform" rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Guggenheim boosted their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Morgan Stanley raised their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an "overweight" rating in a research note on Wednesday, July 8th. Barclays boosted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. Finally, Sanford C. Bernstein upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,289.36.

Eli Lilly and Company Stock Up 4.9%

Shares of NYSE:LLY opened at $1,170.30 on Thursday. The company's fifty day moving average is $1,156.45 and its two-hundred day moving average is $1,045.49. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The stock has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 41.57, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.16 by $2.22. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.69 billion. During the same quarter in the prior year, the business earned $6.31 earnings per share. Eli Lilly and Company's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts anticipate that Eli Lilly and Company will post 34.71 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently made changes to their positions in the company. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $30,000. E Fund Management Hong Kong Co. Ltd. grew its stake in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after acquiring an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC increased its holdings in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock valued at $37,000 after purchasing an additional 20 shares during the period. Finally, Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat and raised outlook: Lilly reported $22.97 billion in second-quarter revenue, up approximately 48% year over year and well above the roughly $20.7 billion consensus estimate. Non-GAAP EPS of $8.38 also exceeded expectations of about $6.16. Management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and provided EPS guidance of $35.50-$36.50. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand remains the main catalyst: Sales of Mounjaro and Zepbound surged, together accounting for nearly two-thirds of quarterly revenue; Mounjaro sales reportedly rose 91%. Strong volume and international expansion are driving growth and helping Lilly widen its lead over Novo Nordisk in the obesity-drug market. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Wall Street remains bullish: Analysts continue to see upside after the beat-and-raise quarter, with at least one major analyst increasing its price target. Coverage describes the results as strengthening Lilly’s long-term investment thesis. We're increasing our Eli Lilly price target after another beat-and-raise quarter
• Positive Sentiment: Pipeline and competitive momentum: Lilly is expanding early access to experimental obesity treatment retatrutide, while investigational cancer drug olomorasib received an FDA breakthrough therapy designation. Novo Nordisk’s recent key miss further highlights Lilly’s competitive advantage in GLP-1 therapies.
• Neutral Sentiment: Key risks remain: Lilly’s growth is heavily concentrated in GLP-1 medicines, and manufacturing capacity could limit its ability to meet demand. At roughly $1.10 trillion in market value and a forward-looking premium valuation, the stock may remain sensitive to future execution, supply, and clinical results.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source